COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04400890

Marvin R McCreary

supplement4covid19@gmail.com

2020-05-26

Terminated

RCT

Randomized

Parallel

Blind label

single-center

Treatment

inclusion criteria: - outpatients who test positive for infection with sars-cov-2. - age ≥45 years - mild covid-19 based on world health organization (who) baseline severity categorization - symptom duration ≤ 10 days, or <72 hours of new respiratory symptoms. - patient must have access to the internet or a smartphone to complete surveys. - english-speaking patients

- diagnosed or suspected cognitive impairment that would prevent the patient from cooperating with study procedures, as judged by the screening clinician - asymptomatic patients (e.g. patients who were screened without symptoms but tested positive) - known or suspected liver disease or hepatitis c - known kidney disease with estimate glomerular filtration rate (egfr) <60 - patients on warfarin, novel oral anticoagulants (noacs), hiv protease inhibitors, immunosuppressants, hydroxychloroquine/chloroquine, and other medication with a narrow therapeutic window. - allergy to grapes or rice. - co-morbidities with a high likelihood of hospitalization within 30 days (e.g., current cancer treatment, severe chronic obstructive pulmonary disease (copd) or congestive heart failure (chf)) - currently pregnant - hospitalization

2

Marvin McCreary, MD

45

100

United States

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

105

Hospitalization rates for COVID-19

None

Phase 2

[{"arm_notes": "", "treatment_id": 1693, "treatment_name": "Resveratrol+vitamin d3", "treatment_type": "Nutrition+vitamins and dietary supplements", "pharmacological_treatment": "Non pharmacological treatment+pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1371, "treatment_name": "Vitamin d3", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}]